PWA
CCCC icon

Physician Wealth Advisors’s C4 Therapeutics CCCC Stock Holding History

Physician Wealth Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-472
Closed -$756 – 1839
2025
Q1 		$756 Buy
+472
New +$1.41K ﹤0.01% 1254

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Physician Wealth Advisors's CCCC Position: Q2 2025 in Review

Physician Wealth Advisors sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 472 shares — an estimated $756 sold.

Physician Wealth Advisors first reported a position in CCCC in Q1 2025 and held it in 1 quarter. The position peaked at $756 in Q1 2025. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • Physician Wealth Advisors reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Physician Wealth Advisors sold 472 C4 Therapeutics shares in Q2 2025, an estimated $756.
  • Physician Wealth Advisors first reported a position in C4 Therapeutics in Q1 2025 and held it in 1 quarter.
  • Physician Wealth Advisors's C4 Therapeutics position peaked at $756 in Q1 2025.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on Physician Wealth Advisors's 13F filing for Q2 2025, filed 14 Jul 2025.